[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495944":3},{"organization":4,"armGroups":7,"interventions":43,"overallOfficials":67,"centralContacts":71,"locations":77,"responsibleParty":130,"collaborators":49,"id":132,"slug":133,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":49,"eligibilityCriteria":138,"healthyVolunteers":134,"sex":139,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":49,"studyType":145,"phases":146,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":94,"whyStopped":49,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},{"fullName":5,"class":6},"Praxis Precision Medicines","INDUSTRY",[8,14,19,25,30,33,38,41],{"label":9,"type":10,"description":11,"interventionNames":12},"Preliminary Safety","EXPERIMENTAL","Open-label PRAX-222",[13],"Drug: PRAX-222 - Initial Dose",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose Escalation - PRAX-222","Initial dose escalation consisting of double-blind ascending doses of PRAX-222",[18],"Drug: PRAX-222 - Initial Ascending Doses",{"label":20,"type":21,"description":22,"interventionNames":23},"Dose Escalation - Placebo","PLACEBO_COMPARATOR","Double-blind placebo procedure",[24],"Procedure: Placebo",{"label":26,"type":10,"description":27,"interventionNames":28},"Optional Dose Escalation - PRAX-222","Optional dose escalation consisting of double-blind ascending doses of PRAX-222",[29],"Drug: PRAX-222 - Optional Ascending Doses",{"label":31,"type":21,"description":22,"interventionNames":32},"Optional Dose Escalation - Placebo",[24],{"label":34,"type":10,"description":35,"interventionNames":36},"Confirmatory Dosing - PRAX-222","Double-blind fixed-dose PRAX-222",[37],"Drug: PRAX-222 - Fixed Doses",{"label":39,"type":10,"description":22,"interventionNames":40},"Confirmatory Dosing - Placebo",[24],{"label":11,"type":10,"description":11,"interventionNames":42},[37],[44,50,54,58,62],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":49},"DRUG","PRAX-222 - Initial Dose","PRAX-222",[9],null,{"type":45,"name":51,"description":52,"armGroupLabels":53,"otherNames":49},"PRAX-222 - Initial Ascending Doses","Ascending doses of PRAX-222",[15],{"type":45,"name":55,"description":56,"armGroupLabels":57,"otherNames":49},"PRAX-222 - Optional Ascending Doses","Escalation of PRAX-222 dose(s)",[26],{"type":45,"name":59,"description":60,"armGroupLabels":61,"otherNames":49},"PRAX-222 - Fixed Doses","Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222",[34,11],{"type":63,"name":64,"description":65,"armGroupLabels":66,"otherNames":49},"PROCEDURE","Placebo","Placebo procedure",[39,20,31],[68],{"name":69,"affiliation":5,"role":70},"Medical Director","STUDY_DIRECTOR",[72],{"name":73,"role":74,"phone":75,"phoneExt":49,"email":76},"Head of Pharmacovigilance","CONTACT","617-300-8460","clinicaltrials@praxismedicines.com",[78,92,115],{"facility":79,"status":80,"city":81,"state":82,"zip":83,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":91,"contacts":49},"Le Bonheur Childrens Hospital","COMPLETED","Memphis","Tennessee","38103","United States","US",{"type":87,"coordinates":88},"Point",[89,90],-90.04898,35.14953,{"lat":90,"lon":89},{"facility":93,"status":94,"city":95,"state":96,"zip":97,"country":98,"countryCode":99,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Hospital de Clinicas de Porto Alegre","RECRUITING","Porto Alegre","Rio Grande do Sul","90035-003","Brazil","BR",{"type":87,"coordinates":101},[102,103],-51.23019,-30.03283,{"lat":103,"lon":102},[106,110,112],{"name":107,"role":74,"phone":108,"phoneExt":49,"email":109},"Bruna de Souza, Research Coordinator","+55 513-359-6343","bpinheiro@hcpa.edu.br",{"name":111,"role":74,"phone":49,"phoneExt":49,"email":49},"Larissa Pozzebon da Silva, Research Coordinator",{"name":113,"role":114,"phone":49,"phoneExt":49,"email":49},"Roberto Giugliani","PRINCIPAL_INVESTIGATOR",{"facility":116,"status":94,"city":117,"state":49,"zip":118,"country":98,"countryCode":99,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Praxis Research Site","São Paulo","05403-010",{"type":87,"coordinates":120},[121,122],-46.63611,-23.5475,{"lat":122,"lon":121},[125,128],{"name":126,"role":74,"phone":49,"phoneExt":49,"email":127},"Alessandra Vieira","alevrodrigues@gmail.com",{"name":129,"role":114,"phone":49,"phoneExt":49,"email":49},"Kette Valente, MD",{"type":131,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":49,"oldNameTitle":49,"oldOrganization":49},"SPONSOR","100495944","phase-1-a-clinical-trial-of-prax-222-in-pediatric-participants-with-early-onset-scn2a-developmental-and-epileptic-encephalopathy-100495944",false,"NCT05737784","A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy","A Seamless, Clinical Trial to Investigate the Safety and Efficacy of Multiple Doses of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy","Inclusion Criteria:\n\n* Has onset of seizures prior to 3 months of age.\n* Has a minimum weight of at least 10 kg at screening.\n* Has a documented SCN2A variant through genetic testing obtained via a laboratory accredited per Clinical Laboratory Improvement Amendments (CLIA) or College of American Pathologists (CAP) or equivalent.\n* Additional inclusion criteria apply and will be assessed by the study team\n\nExclusion Criteria:\n\n* Has any clinically significant or known pathogenic genetic variant other than in the SCN2A gene, or a genetic variant that may explain or contribute to the participant's epilepsy and\u002For developmental disorder.\n* Is taking more than 2 sodium channel blocking anti-seizure medications\n* Additional exclusion criteria apply and will be assessed by the study team","ALL","2 Years","18 Years",{"count":143,"type":144},60,"ESTIMATED","INTERVENTIONAL",[147,148],"PHASE1","PHASE2","The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.",[151,152],"SCN2A-DEE","Epilepsy",[154,155,156,157,158,159,160],"Antisense Oligonucleotide","NaV1.2 Voltage-Gated Sodium Channel","Voltage-Gated Sodium Channel Blockers","SCN2A variant","Pediatric epilepsy","Developmental and Epileptic Encephalopathy","DEE","2025-08-15",{"date":163,"type":164},"2025-08-21","ACTUAL",{"date":166,"type":164},"2023-04-13",{"date":168,"type":144},"2027-09",{"name":5,"class":6},3]